Lakefront Biotherapeutics NV (LKFT) — Net Asset Quality Index
Lakefront Biotherapeutics NV (LKFT) has a Net Asset Quality Index of 97.4% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $3.35 Billion minus total liabilities of $87.52 Million yields net assets of $3.26 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check cash flow quality index of Lakefront Biotherapeutics NV to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Lakefront Biotherapeutics NV Net Asset Quality Index Over Time (2022–2025)
This chart shows how Lakefront Biotherapeutics NV's Net Asset Quality Index has evolved across 4 annual periods from 2022 to 2025. As of June 2026, the index stands at 97.4%, representing net assets of $3.26 Billion against total assets of $3.35 Billion USD. See Lakefront Biotherapeutics NV book value and equity for net asset value and shareholders' equity analysis.
Annual Net Asset Quality Index for Lakefront Biotherapeutics NV (2022–2025)
The table below presents the year-by-year Net Asset Quality Index for Lakefront Biotherapeutics NV from 2022 to 2025, covering 4 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Lakefront Biotherapeutics NV market cap and net worth.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 95.0% | $3.24 Billion | $3.41 Billion | $170.65 Million | ▲ +24.9 pp |
| 2024 | 70.0% | $2.90 Billion | $4.14 Billion | $1.24 Billion | ▲ +5.9 pp |
| 2023 | 64.2% | $2.80 Billion | $4.36 Billion | $1.56 Billion | ▲ +10.8 pp |
| 2022 | 53.4% | $2.53 Billion | $4.73 Billion | $2.21 Billion | — |